Sherbrooke Park Advisers LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Sherbrooke Park Advisers LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,092 shares of the biopharmaceutical company's stock, valued at approximately $1,329,000. Pfizer makes up about 0.4% of Sherbrooke Park Advisers LLC's holdings, making the stock its 19th largest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth about $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the 4th quarter valued at about $28,000. Finally, Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter worth about $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 1.0%

PFE traded up $0.23 during trading hours on Friday, reaching $22.83. The company's stock had a trading volume of 37,727,922 shares, compared to its average volume of 40,925,832. The stock has a market cap of $129.77 billion, a PE ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business's 50-day moving average is $23.65 and its 200-day moving average is $25.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.82 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.